Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series. - Sherman AC; van Haren SD; Borberg E; Swank Z; Aleissa M; Tong A; Rooks R; Kanwal U; Levine H; Yates B; Izaguirre N; Ryff K; et al. (Vaccine, 2024)